Medical Watchdog Urges Endocrine Society to Reevaluate Support for Trans Medicine on Minors

A Medical Watchdog Organization Urges Endocrine Society to Review Stance on Transgender Medical Interventions

A medical watchdog organization called Do No Harm is urging the Endocrine Society to conduct a "systematic review" of its endorsement of medical interventions aimed at changing the sex of minors. The organization is concerned about the increasing skepticism towards transgender medical interventions in Europe. The Endocrine Society supports "gender-affirming care," which includes the use of puberty blockers, cross-sex hormone therapy, and surgical procedures such as double mastectomies. The letter from Do No Harm emphasizes the need to protect healthcare from what it perceives as a radical and discriminatory ideology.

Criticism of Endocrine Society's Stance on Medical Gender Transition for Children

A letter from an organization called Do No Harm criticizes the Endocrine Society's stance on medical gender transition for children. The letter questions the Society's certainty about the benefits outweighing the risks and suggests that their approach is misguided and potentially dangerous for young people.

Call for Updated Guidelines on Transgender Medical Interventions

A letter has been written to the Endocrine Society, urging them to update their guidelines on transgender medical interventions. The letter points out that the society has not acknowledged the changes happening in Europe regarding transgender policies. It suggests that if even socially liberal countries are questioning the empirical foundations of pediatric gender medicine, the society should explain its stance.

Disagreement Among Medical Professionals on Treatment of Transgender Children

The article discusses a disagreement between two medical professionals regarding the treatment of transgender children. The first article claims that medical professionals are being forced to provide dangerous treatments to children, while the second article argues that this claim ignores scientific evidence and the conclusions of reputable medical organizations.

Endocrine Society's Response and Funding

The Endocrine Society, a medical organization, has not responded to a letter from Do No Harm, which raises concerns about medical transitions. The society has received funding from pharmaceutical company Abbvie, which manufactures Lupron Depot, a drug used for chemical castration and off-label to block puberty in transgender adolescents.

AbbVie Discontinues Production of Transgender Hormone Therapy Patch

AbbVie, a pharmaceutical company, has discontinued the production of Androderm, a trans-dermal testosterone patch used for cross-sex hormone therapy by women transitioning to men. The discontinuation was reportedly due to a shortage. The Endocrine Society, which oversees medical interventions for transgender individuals, has not responded to a letter from a group called Do No Harm, which opposes transgender medical interventions. However, the American Academy of Pediatrics has announced that it will be conducting a review of the evidence surrounding "gender-affirming care."